BR0209948A - Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos - Google Patents

Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos

Info

Publication number
BR0209948A
BR0209948A BR0209948-9A BR0209948A BR0209948A BR 0209948 A BR0209948 A BR 0209948A BR 0209948 A BR0209948 A BR 0209948A BR 0209948 A BR0209948 A BR 0209948A
Authority
BR
Brazil
Prior art keywords
methods
identifying
macrophage migration
migration inhibitory
mif
Prior art date
Application number
BR0209948-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Federico C A Gaeta
Andrew Baird
Jerry Anchin
Wenbin Ying
Robert Florkiewicz
Jagadish Sircar
Kumar K C Sunil
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of BR0209948A publication Critical patent/BR0209948A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR0209948-9A 2001-05-24 2002-05-24 Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos BR0209948A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29364201P 2001-05-24 2001-05-24
PCT/US2002/016963 WO2002094203A2 (en) 2001-05-24 2002-05-24 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

Publications (1)

Publication Number Publication Date
BR0209948A true BR0209948A (pt) 2004-12-21

Family

ID=23129922

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209948-9A BR0209948A (pt) 2001-05-24 2002-05-24 Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos

Country Status (24)

Country Link
US (14) US7105519B2 (enExample)
EP (1) EP1389110B1 (enExample)
JP (1) JP4346312B2 (enExample)
KR (1) KR100896973B1 (enExample)
CN (1) CN1523989A (enExample)
AR (1) AR036032A1 (enExample)
AT (1) ATE461920T1 (enExample)
AU (2) AU2002303906B2 (enExample)
BR (1) BR0209948A (enExample)
CA (1) CA2447103A1 (enExample)
CZ (1) CZ20033503A3 (enExample)
DE (1) DE60235750D1 (enExample)
ES (1) ES2342877T3 (enExample)
HU (1) HUP0500101A3 (enExample)
IL (1) IL158550A0 (enExample)
MX (1) MXJL03000038A (enExample)
MY (1) MY140679A (enExample)
NZ (1) NZ529244A (enExample)
PL (1) PL367127A1 (enExample)
PT (1) PT1389110E (enExample)
RU (1) RU2327695C2 (enExample)
UY (1) UY27304A1 (enExample)
WO (1) WO2002094203A2 (enExample)
ZA (1) ZA200309738B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002255961B2 (en) 2001-03-29 2007-08-23 Baxalta GmbH Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP2270505A1 (en) 2002-04-26 2011-01-05 Takeda Pharmaceutical Company Limited A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF)
AU2003247772A1 (en) 2002-06-27 2004-01-19 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7364869B2 (en) * 2003-07-29 2008-04-29 The J. David Gladstone Institutes Method of detecting antigen-specific T lymphocytes
MXJL06000006A (es) * 2003-08-22 2006-05-04 Avanir Pharmaceuticals Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
AU2011265309B2 (en) * 2003-11-21 2014-06-05 Array Biopharma, Inc. AKT protein kinase inhibitors
JP2007512364A (ja) 2003-11-21 2007-05-17 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼインヒビター
US20080305118A1 (en) * 2004-03-29 2008-12-11 The Feinstein Institute For Medical Research Treatment Of Type 1 Diabetes With Inhibitors Of Macrophage Migration Inhibitory Factor
DE102004029573A1 (de) * 2004-06-18 2005-12-29 Gambro Lundia Ab MIF-Adsorbent
WO2006031199A1 (en) * 2004-09-17 2006-03-23 Alex Poh Teck Choong System and method for batch conversion of rfid tag to rfid label
JP2008534502A (ja) * 2005-03-24 2008-08-28 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としてのチエノピリジノン誘導体
PL1928438T3 (pl) * 2005-09-26 2013-08-30 Avigen Inc Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających
GB0605689D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
AU2007230948B2 (en) * 2006-03-24 2012-06-28 The Feinstein Institute For Medical Research Modified macrophage migration inhibitory factor inhibitors
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
EP2026804A1 (en) * 2006-05-31 2009-02-25 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes
US7845914B2 (en) * 2007-02-15 2010-12-07 Deere & Company Self-priming fast fill sprayer pump system
WO2009045543A1 (en) * 2007-10-04 2009-04-09 The Regents Of The University Of California Treatment of conditions related to shock
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
PT2592933T (pt) * 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
WO2012031383A1 (zh) * 2010-09-06 2012-03-15 中国科学院广州生物医药与健康研究院 酰胺类化合物
EP2621521A4 (en) 2010-10-02 2014-04-23 Univ California MINIMIZING DARMDYS FUNCTIONS
EP2748613B1 (en) 2011-10-07 2021-05-05 Baxalta GmbH Oxmif as a diagnostic marker
KR20130118612A (ko) * 2012-04-20 2013-10-30 (주)네오믹스 신규한 아미노피리딘 유도체 및 이의 용도
EP2844250B1 (en) 2012-05-01 2017-11-08 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US9549988B2 (en) 2013-06-09 2017-01-24 RJS Biologics Pharmaceutical compounds targeted by MIF affinity-tethered moieties
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
US10696637B2 (en) * 2015-07-17 2020-06-30 Fujifilm Corporation Nitrogen-containing heterocyclic compound
CN111518077B (zh) * 2018-01-17 2021-02-26 杭州阿诺生物医药科技有限公司 一种新型抗肿瘤ido抑制剂的制备方法
CA3096838A1 (en) 2018-04-11 2019-10-17 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
CN119330979A (zh) 2018-04-13 2025-01-21 癌症研究技术有限公司 作为bcl6抑制剂的化合物及其制备方法
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
EA202190137A1 (ru) 2018-06-27 2021-05-17 Бристол-Маерс Сквибб Компани Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
AU2020415377A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as T cell activators
KR20220120624A (ko) 2019-12-23 2022-08-30 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 피페라진 유도체
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
EP4081513B1 (en) * 2019-12-23 2024-11-20 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
CN113121435B (zh) * 2021-04-20 2022-08-30 辽宁大学 一种2,4-二氯喹啉类化合物的合成方法
CN119074725A (zh) * 2024-09-11 2024-12-06 北京大学第一医院(北京大学第一临床医学院) 靶向mif在制备用于治疗特应性皮炎的药物中应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4284768A (en) * 1980-07-02 1981-08-18 American Home Products Corporation 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
ZW2485A1 (en) 1984-02-22 1986-09-24 Wellcome Found Cloning of dna for protozoal antigens
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5801200A (en) 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733524A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
AU592753B2 (en) 1984-05-24 1990-01-25 Ciba-Geigy Ag Lymphokine in pure foem, novel monoclonal antibodies hybridoma cell lines, processes and applications
JPH0672158B2 (ja) 1984-05-24 1994-09-14 チバ−ガイギ− アクチエンゲゼルシヤフト 精製されたヒトマクロファージ遊走阻止因子
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8602626D0 (en) 1986-02-04 1986-03-12 Ciba Geigy Ag Neurite-promoting factor
DE3789413T2 (de) 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463037A1 (en) 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor
FI82144C (fi) 1989-03-22 1991-01-10 Wallac Oy Foerfarande foer samtidig bestaemning av flera ligander.
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5328990A (en) 1991-04-26 1994-07-12 The United States Of America As Represented By The Department Of Health And Human Services Isolation of macrophage migration inhibition factor from ocular lens
CA2054602C (en) 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JP4708510B2 (ja) 1993-05-17 2011-06-22 サイトカイン ファーマサイエンシズ，インコーポレーテッド サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5650295A (en) 1995-06-02 1997-07-22 Human Genone Sciences, Inc. Macrophage migration inhibitory factor-3
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
US5955203A (en) 1994-10-05 1999-09-21 Simpson Timber Company Resin-coated overlays for solid substrates
AU4365796A (en) 1994-11-16 1996-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
DE19601697A1 (de) 1996-01-18 1997-07-24 Wacker Chemie Gmbh Redispergierbare Tackifierpulver
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
JP2000512737A (ja) 1996-04-18 2000-09-26 アリアッド ファーマスーティカルズ，インク． 試験管内蛍光偏光検定法
US5883224A (en) 1996-04-19 1999-03-16 Cytokine Sciences, Inc. Characterization of transfer factors and methods of use
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
US6413939B1 (en) 1997-10-31 2002-07-02 The Picower Institute For Medical Research Inducible phosphofructokinase and the Warburg effect
WO2000007007A1 (en) 1998-07-28 2000-02-10 Biometric Imaging, Inc. Device and method for cell motility assay
EP1102848B1 (en) * 1998-08-07 2010-10-13 Immunex Corporation Molecules designated ldcam
US6214343B1 (en) 1999-05-24 2001-04-10 Ophidian Pharmaceuticals, Inc. Prevention and treatment of necrotizing enterocolitis
EP1228037A4 (en) 1999-10-29 2004-06-02 Picower Inst Med Res COMPOUNDS HAVING ANTIAGONIST ACTIVITY OF MIF
WO2002067862A2 (en) 2001-01-12 2002-09-06 Cytokine Pharmasciences, Inc. Regulation of the ctl response by macrophage migration inhibitory factor
AU2002255961B2 (en) 2001-03-29 2007-08-23 Baxalta GmbH Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
MY140679A (en) * 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
WO2003020719A1 (en) 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and use thereof
FR2829491B1 (fr) 2001-09-12 2005-09-30 Diverchim Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase
AU2002365941A1 (en) 2001-12-05 2003-09-02 North Shore-Long Island Jewish Research Institute Methods of diagnosis, monitoring and treatment of fertility
US20040019921A1 (en) 2001-12-19 2004-01-29 Fingerle-Rowson Gunter R. Non-human mammal with disrupted or modified MIF gene, and uses thereof
EP2270505A1 (en) 2002-04-26 2011-01-05 Takeda Pharmaceutical Company Limited A method of screening a cell death inhibitor using macrophage migration inhibitory factor (MIF)
JP2006511445A (ja) 2002-06-07 2006-04-06 コーティカル・ピーティーワイ・リミテッド マクロファージ遊走阻止因子（ｍｉｆ）のサイトカインまたは生物学的活性を阻害するナフタレン誘導体
CN100558712C (zh) 2002-06-07 2009-11-11 科蒂科股份有限公司 治疗分子及方法-1
OA12927A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors.
WO2004060881A1 (ja) 2002-12-05 2004-07-22 Takeda Pharmaceutical Company Limited １，３−ベンゾチアジノン誘導体、その製造法および用途
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7361474B2 (en) 2003-02-24 2008-04-22 United States Of America As Represented By The Department Of Veterans Affairs Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer
MXJL06000006A (es) 2003-08-22 2006-05-04 Avanir Pharmaceuticals Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
JP2008534502A (ja) * 2005-03-24 2008-08-28 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としてのチエノピリジノン誘導体

Also Published As

Publication number Publication date
NZ529244A (en) 2006-04-28
ES2342877T3 (es) 2010-07-16
AR036032A1 (es) 2004-08-04
EP1389110A2 (en) 2004-02-18
US7230106B2 (en) 2007-06-12
US20060205734A1 (en) 2006-09-14
KR20040041095A (ko) 2004-05-13
US7192961B2 (en) 2007-03-20
JP2005500266A (ja) 2005-01-06
CZ20033503A3 (cs) 2004-08-18
ATE461920T1 (de) 2010-04-15
US7202248B2 (en) 2007-04-10
US20070021440A1 (en) 2007-01-25
ZA200309738B (en) 2004-10-04
MY140679A (en) 2010-01-15
UY27304A1 (es) 2002-12-31
US7105519B2 (en) 2006-09-12
CA2447103A1 (en) 2002-11-28
US7432374B2 (en) 2008-10-07
US7129236B2 (en) 2006-10-31
PT1389110E (pt) 2010-07-01
WO2002094203A3 (en) 2003-04-10
RU2003132534A (ru) 2005-04-20
US20060235023A1 (en) 2006-10-19
US20070197547A1 (en) 2007-08-23
US20060199825A1 (en) 2006-09-07
US7732146B2 (en) 2010-06-08
US20050282236A1 (en) 2005-12-22
IL158550A0 (en) 2004-05-12
US20050287617A1 (en) 2005-12-29
US7192955B2 (en) 2007-03-20
US20070232613A1 (en) 2007-10-04
AU2007201493A1 (en) 2007-04-26
EP1389110B1 (en) 2010-03-24
AU2002303906B2 (en) 2007-06-28
HUP0500101A3 (en) 2009-09-28
MXJL03000038A (es) 2004-12-03
US20060194818A1 (en) 2006-08-31
US20060199827A1 (en) 2006-09-07
US7235565B2 (en) 2007-06-26
CN1523989A (zh) 2004-08-25
KR100896973B1 (ko) 2009-05-14
HUP0500101A2 (hu) 2005-05-30
US20030195194A1 (en) 2003-10-16
US7084141B2 (en) 2006-08-01
EP1389110A4 (en) 2004-10-20
JP4346312B2 (ja) 2009-10-21
US7435737B2 (en) 2008-10-14
US20060194793A1 (en) 2006-08-31
US7514225B2 (en) 2009-04-07
US7157469B2 (en) 2007-01-02
US7238809B2 (en) 2007-07-03
RU2327695C2 (ru) 2008-06-27
US20060194792A1 (en) 2006-08-31
US20060094727A1 (en) 2006-05-04
DE60235750D1 (de) 2010-05-06
WO2002094203A2 (en) 2002-11-28
PL367127A1 (en) 2005-02-21

Similar Documents

Publication Publication Date Title
BR0209948A (pt) Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos
BRPI0413695A (pt) derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas
MY142846A (en) Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
BR0312464A (pt) Inibidores de tirosina quinases
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
BR0013248A (pt) Inibidores da adesão celular
BRPI0510394A (pt) inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1
UY29246A1 (es) Nuevos compuestos
BRPI0315143B8 (pt) composto, composição farmacêutica, e, uso de um composto
WO2007109251A3 (en) Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
BR0008958A (pt) Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc
BR0208373A (pt) Inibidores da tirosina cinase
BRPI0408784A (pt) método para usar um composto
ECSP034896A (es) Derivados aromaticos de acidos dicarboxilicos
UY28514A1 (es) Nuevos compuestos
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
SE0302323D0 (sv) Novel compounds
EE9800141A (et) Amidiini ja isotiokarbamiidi derivaadid lämmastikoksiidi süntaasi inhibiitoritena
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
SE0202461D0 (sv) Novel compounds
BR0110490B1 (pt) agentes de tingimento contendo derivados de n-heteroarilmetil-m-fenilenodiamina para fibras de queratina bem como novos derivados de n-heteroarilmetil-m-fenilenodiamina.
BRPI0417263A (pt) imidazopiridinas para uso como inibidores de secreção gástrica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]